Michael Geffner
Direttore Tecnico/Scientifico/R&S presso IMMUNOVANT, INC.
Patrimonio netto: 4 M $ in data 30/06/2024
Provenienza dei contatti di primo grado di Michael Geffner
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 31 | |
| Public Company | Biotechnology | 20 | |
BlueSphere Bio, Inc.
 BlueSphere Bio, Inc. Pharmaceuticals: MajorHealth Technology BlueSphere Bio, Inc. manufactures oncology drugs products. The company was founded by Mark Shlomchik, Warren Shlomchik, and Constantinos Panousis and is headquartered in Pittsburgh, PA.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Michael Geffner tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chairman Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
OraPharma, Inc.
 OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Pharmaceuticals: Major | Founder Chief Executive Officer General Counsel Chief Operating Officer Comptroller/Controller/Auditor | |
| The Leonard N Stern School of Business | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree Undergraduate Degree | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal President | |
| University of Pennsylvania | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| The Pennsylvania State University | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
IEcure, Inc.
 IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Biotechnology | Chief Executive Officer Director/Board Member Chief Operating Officer | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Director/Board Member | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| Yale University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| PROGENICS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| PURETECH HEALTH PLC | Biotechnology | Chief Tech/Sci/R&D Officer Investor Relations Contact | |
| EARGO, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
| MARINUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman General Counsel | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Chairman Director/Board Member | |
NeoTract, Inc.
 NeoTract, Inc. BiotechnologyHealth Technology NeoTract, Inc. develops surgical devices for urological and gynecological disorders. It offers UroLift System, a minimally invasive device to treat lower urinary tract symptoms due to benign prostatic hyperplasia. The company was founded by Joshua Makower, Joseph Catanese, Theodore C. Lamson and Earl A. Bright II in 2004 and is headquartered in Pleasanton, CA. | Biotechnology | Director of Finance/CFO Director/Board Member | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Director of Finance/CFO Investor Relations Contact | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Sales & Marketing Director/Board Member | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| UNIQURE N.V. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ZOETIS INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
| IMMUNOMEDICS, INC. | Biotechnology | Investor Relations Contact Chief Tech/Sci/R&D Officer | |
| St. Joseph's University | College/University | Masters Business Admin Masters Business Admin | |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company was founded on July 21, 2003 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Executive Officer Chairman | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Spear Therapeutics Ltd.
 Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Synthesis Capital
 Synthesis Capital Investment ManagersFinance Synthesis Capital is a venture capital firm founded in 2007. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 46 |
| Regno Unito | 3 |
| Bermuda | 2 |
| Paesi Bassi | 2 |
| Australia | 2 |
Settori
| Health Technology | 38 |
| Consumer Services | 9 |
| Commercial Services | 4 |
| Finance | 3 |
Posizioni
| Director/Board Member | 198 |
| Corporate Officer/Principal | 107 |
| Independent Dir/Board Member | 55 |
| Chairman | 40 |
| Undergraduate Degree | 40 |
Contatti più connessi
| Insiders | |
|---|---|
| Frank Torti | 35 |
| Jason S. Fisherman | 30 |
| Nicole Vitullo | 29 |
| Robert van Nostrand | 22 |
| Atul Pande | 21 |
| Jonathan Peacock | 21 |
| David I. Scheer | 19 |
| George Migausky | 18 |
| Andrew Fromkin | 16 |
| Frank Verwiel | 16 |
| Kurt Graves | 15 |
| Douglas Hughes | 15 |
| Martha Manning | 13 |
| Steven Zelenkofske | 13 |
| Brian DiDonato | 13 |
- Borsa valori
- Insiders
- Michael Geffner
- Connessioni Società
